Figure 1.

Structural depiction of the unconjugated, unlabelled mAb used for pre-dosing (anti-TENB2, left) and the radiolabelled anti-TENB2-MMAE under evaluation ([¹¹¹In]-DOTA-anti-TENB2-MMAE, right). The auristatin drug, MMAE (green), was conjugated site-specifically to exactly two engineered thiols via the protease-labile maleimido-caproyl-valine-citrulline-para-amino-benzyloxy carbonyl (MC-vc-PAB) linker, while the radiometal chelate, DOTA (yellow), was randomly conjugated to lysine residues through amide bonds.